A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. Experts ...

Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...

Trump could keep Biden’s commitment to have Medicare pay for weight loss drugs such as Ozempic and Wegovy. But would ...

Ozempic, Wegovy and Mounjaro, all GLP-1 anti-obesity medications, may offer health benefits beyond weight loss. Studies show ...

GLP-1 drugs such as Ozempic and Wegovy are driving down grocery spending, according to a new study from Cornell’s SC Johnson ...

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

How GLP-1 therapies could help build a healthier, more productive workforce—and what that would mean for how we live together ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

For weight loss drugs like Ozempic and Wegovy, 2024 was a big year. More patients are relying on them to manage their weight, treat diabetes, or prevent heart attacks and strokes. And while they are ...

Surgeons are collaborating with obesity medicine physicians, turning to GLP-1s to help high BMI patients qualify for surgery.

With 13 states offering coverage, it’s already a $3.9 billion cost. Some state officials say reducing obesity will save programs money in the long run.

For the past two years, Ozempic and Wegovy have dominated the conversation when it comes to weight-loss medications (WLMs). The two medications, developed and distributed by Novo Nordisk, have made ...